{"groups":[{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"FG000","title":"P1_C1_5x10^6"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"FG001","title":"P1_C2_1x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"FG002","title":"P1_C3_5x10^7"},{"description":"Patients receive lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"FG003","title":"P1_C4_1X10^8"},{"description":"Patients receive elotuzumab IV over 2-5 hours on day -15 and -8, lenalidomide PO QD on days -8 to -2, high-dose melphalan IV over 30 minutes on day -7, and UCB-derived NK cells IV over 1 hour on day -5. Patients undergo autologous stem cell transplant on day 0.\n\nAutologous Hematopoietic Stem Cell Transplantation: Undergo autologous stem cell transplant\n\nElotuzumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nMelphalan: Given IV\n\nNatural Killer Cell Therapy: Given IV\n\nUmbilical Cord Blood-Derived Lymphocyte Therapy: Given IV","id":"FG004","title":"P2_1x10^8+Elotuzumab"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"32"},{"groupId":"FG004","numSubjects":"30"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"4"},{"groupId":"FG003","numSubjects":"32"},{"groupId":"FG004","numSubjects":"30"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"All participants were registered in MD Anderson Cancer Center."}